INS and type 2 diabetes mellitus: For people aged < 65 years with type 2 diabetes and on intensive insulin therapy, HbA1c reduction was significantly greater in those using CGM for 6 months compared to SMBG, with less time spent in hypoglycaemia, and improved quality of life [21].